The collaboration will provide IDEXX Reference Laboratories’ veterinary customers access to FidoCure Next Generation DNA Sequencing Test.
One Health Company—a company that works toward improving canine cancer care—has partnered with IDEXX Laboratories, Inc—a company focused on global pet healthcare innovation. IDEXX Reference Laboratories will offer the FidoCure Next Generation DNA Sequencing Test to its veterinary clients in the United States and Canada later in January.
“We are tremendously excited to collaborate with a global leader in veterinary diagnostics to help bring our novel FidoCure Next Generation DNA Sequencing Test to even more veterinary clinics across the U.S. and Canada,” said Christina Lopes, co-founder and CEO of One Health Company, in a company release.1 “IDEXX’s customer- and innovation-centric approach to veterinary diagnostics is an ideal complement to FidoCure’s precision medicine platform.”
There is a growing need for improved cancer care in dogs with approximately 6 million new canines diagnosed with the disease each year.2 Dogs are susceptible to genetic mutations that encourage cancer to grow and spread. Detecting these mutations through genetic sequencing and targeted therapy, such as with FidoCure's precision medicine platform, allows for customized treatment and streamlined care for canine cancer patients.
According to the release, more than 2,000 dogs diagnosed with cancer have used the FidoCure Next Generation DNA Sequencing Test. From the results, eligible dogs were offered customized treatment options using targeted therapies approved by the FDA to treat humans. This partnership will enable FidoCure, which currently holds the world's largest proprietary canine cancer dataset, to substantially grow this dataset and reveal new discoveries that could benefit dogs and humans with cancer.
References
